Climb Bio (CLYM) Cash & Equivalents (2020 - 2026)

Climb Bio's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $8.4 million for Q1 2026.

• Quarterly Cash & Equivalents fell 71.21% year-over-year to $8.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.4 million (down 71.21% YoY) and the FY2025 annual result came in at $35.7 million, down 59.09% from the prior year.
• Cash & Equivalents was $8.4 million for Q1 2026 at Climb Bio, down from $35.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $218.1 million in Q2 2024 and bottomed at $8.4 million in Q1 2026.
• A 5-year average of $69.9 million and a median of $35.7 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents jumped 762.33% — and 2025, when it slumped 89.6%.
• Climb Bio's Cash & Equivalents stood at $43.6 million in 2022, then jumped by 136.05% to $102.9 million in 2023, then dropped by 15.22% to $87.2 million in 2024, then plunged by 59.09% to $35.7 million in 2025, then tumbled by 76.58% to $8.4 million in 2026.
• Business Quant data shows CLYM's Cash & Equivalents at $8.4 million in Q1 2026, $35.7 million in Q4 2025, and $25.8 million in Q3 2025.